Similarly, fatostatin inhibits the development of endometrial carcinoma by downregulating SREBP2 and interfering with SREBP2-mediated cholesterol metabolic pathways, further demonstrating anti-tumor effect of downregulated SREBP2 (Gao et al., 2018). Here, SREBF2 is linked to endometrial carcinoma.